Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.46 million versus the consensus estimate of $4.09 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.